An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis

An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis

Abstract Background Dulaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus (T2DM). However, the efficacy and safety of dulaglutide remain unclear in insulin-treated patients with T2DM on maintenance hemodialysis (HD). Meth...

Full description

Bibliographic Details
Main Authors: Daisuke Ugamura, Michihiro Hosojima, Hideyuki Kabasawa, Naohito Tanabe, Yuta Yoshizawa, Yoshiki Suzuki, Akihiko Saito, Ichiei Narita
Format: Article
Language:English
Published: BMC 2022-06-01
Series:Renal Replacement Therapy
Subjects:
Dulaglutide
Glucagon-like peptide-1 receptor agonist
Hemodialysis
Once-weekly
Type 2 diabetes mellitus
Online Access:https://doi.org/10.1186/s41100-022-00409-4

Internet

https://doi.org/10.1186/s41100-022-00409-4

Similar Items